Vol 7, No 2 (2016)
Review paper
Published online: 2016-11-09
Page views
1017
Article views/downloads
8685
Prognostic significance of minimal residual disease assessed by flow cytometry in acute myeloid leukemia
Hematologia 2016;7(2):97-107.
Abstract
Despite high complete remission rate after induction chemotherapy, long-term prognosis for acute myeloid leukemia (AML) patients is still unsatisfactory. Leukemic blast cells remaining after therapy, which cannot be detected by standard method for response assessment in AML, termed minimal residual disease (MRD) are responsible for frequent relapses. High sensitivity methods, e.g. flow cytometry are being widely studied for MRD monitoring. Majority of studies confirm this parameter to be an independent risk factor for relapse and death in AML. What is more, MRD assessment is thought to be complementary to cytogenetic and molecular aberrancies in risk stratification and applying more adequate risk-adapted therapy. However, lack of method standardization is an obstacle to its incorporation into clinical practice.
Keywords: acute myeloid leukemiaminimal residual diseasemultiparameter flow cytometry
References
- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012; 30(20): 2441–2448.
- Surveillance, Epidemiology and end Results. . seer. cancer.gov/statfacts/html/amyl.html (13.09.2016).
- Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol. 2009; 131(1): 16–26.
- Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012; 30(29): 3625–3632.
- Grimwade D, Hills RK, Moorman AV, et al. National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–365.
- Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009: 385–395.
- Buccisano F, Maurillo L, Piciocchi A, et al. Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. Ann Hematol. 2015; 94(8): 1319–1326.
- Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006; 135(2): 165–173.
- Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008; 142(2): 227–237.
- Kayser S, Walter RB, Stock W, et al. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015; 10(2): 132–144.
- Jaso JM, Wang SA, Jorgensen JL, et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014; 49(9): 1129–1138.
- San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997; 90: 2465–2470.
- Al-Mawali A, Gillis D, Hissaria P, et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol. 2008; 129(6): 934–945.
- Grimwade D, Freeman SD, Grimwade D, et al. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood. 2014; 124(23): 3345–3355.
- Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom. 2004; 62(1): 25–38.
- Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012; 119(2): 332–341.
- Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001; 97(11): 3574–3580.
- van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110(7): 2659–2666.
- Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014; 9(9): e107587.
- Paietta E. Should minimal residual disease guide therapy in AML? Best Pract Res Clin Haematol. 2015; 28(2-3): 98–105.
- San Miguel JF, Vidriales MB, López-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001; 98(6): 1746–1751.
- Inoue D, Maruoka H, Takahashi T. Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry. Mediterr J Hematol Infect Dis. 2010; 2(2): e2010020.
- Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia. 2004; 18(8): 1380–1390.
- Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013; 31(31): 3889–3897.
- Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012; 120(8): 1581–1588.
- Vidriales MB, Pérez-López E, Pegenaute C, et al. PETHEMA Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leuk Res. 2016; 40: 1–9.
- Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011; 29(9): 1190–1197.
- Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013; 122(10): 1813–1821.
- Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015; 29(1): 137–144.
- Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant. 2014; 49(5): 679–683.
- Appelbaum FR. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. Best Pract Res Clin Haematol. 2015; 28: 133–140.
- Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013; 31(32): 4123–4131.
- Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11(6): 543–552.
- Maurillo L, Buccisano F, Piciocchi A, et al. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. Am J Hematol. 2015; 90(2): 125–131.
